1	Estimating the contribution of HIV-infected adults to household pneumococcal transmission in
2	South Africa, 2016-2018: A hidden Markov modelling study.
3 4	Authors
5	Deus Thindwa ^{1,2*} , Nicole Wolter ^{3,4} , Amy Pinsent ^{1,5} , Maimuna Carrim ³ , John Ojal ^{1,6} , Stefano
6	Tempia ^{3,7,8,9} , Jocelyn Moyes ³ , Meredith McMorrow ⁸ , Jackie Kleynhans ^{3,10} , Anne von Gottberg ^{3,4} , Neil
7	French ^{2,11} , Cheryl Cohen ^{3,10‡} , Stefan Flasche ^{1‡} on behalf of PHIRST group [†]
8 9	¹ Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease
10	Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
11	² Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
12	³ Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of
13	the National Health Laboratory Service, Johannesburg, South Africa.
14	⁴ School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
15	⁵ Aquarius Population Health, London, UK.
16	⁶ KEMRI-Wellcome Trust Research Programme, Geographic Medicine Centre, Kilifi, Kenya.
17	⁷ Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.
18	⁸ Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
19	⁹ MassGenics, Duluth, Georgia, USA.
20	¹⁰ School of Public Health, Faculty of Health Science, University of the Witwatersrand, Johannesburg,
21	South Africa.
22	¹¹ Institute of Infection, Veterinary and Ecological Science, Department of Clinical Infection,
23	Microbiology, and Immunology, University of Liverpool, Liverpool, UK.
24 25	‡ These authors contributed equally
26	† Membership of the PHIRST group is provided in the Acknowledgements.
27 28	* Corresponding author
29	Email: deus.thindwa@gmail.com
30	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 Abstract

32 Human immunodeficiency virus (HIV) infected adults are at a higher risk of pneumococcal 33 colonisation and disease, even while receiving antiretroviral therapy (ART). To help evaluate 34 potential indirect effects of vaccination of HIV-infected adults, we assessed whether HIV-infected 35 adults disproportionately contribute to household transmission of pneumococci. We constructed a 36 hidden Markov model to capture the dynamics of pneumococcal carriage acquisition and clearance 37 observed during a longitudinal household-based nasopharyngeal swabbing study, while accounting 38 for sample misclassifications. Households were followed-up twice weekly for 10 months for 39 nasopharyngeal carriage detection via real-time PCR. We estimated the effect of participant's age, 40 HIV status, presence of a HIV-infected adult within the household and other covariates on 41 pneumococcal acquisition and clearance probabilities. Of 1,684 individuals enrolled, 279 (16.6%) 42 were younger children (<5 years-old) of whom 4 (1.5%) were HIV-infected and 726 (43.1%) were 43 adults (≥18 years-old) of whom 214 (30.4%) were HIV-infected, most (173, 81.2%) with high CD4+ 44 count. The observed range of pneumococcal carriage prevalence across visits was substantially higher 45 in younger children (56.9-80.5%) than older children (5-17 years-old) (31.7-50.0%) or adults (11.5-46 23.5%). We estimate that 14.4% (95% Confidence Interval [CI]: 13.7-15.0) of pneumococcal-47 negative swabs were false negatives. Daily carriage acquisition probabilities among HIV-uninfected 48 younger children were similar in households with and without HIV-infected adults (hazard ratio: 0.95, 49 95%CI: 0.91-1.01). Longer average carriage duration (11.4 days, 95%CI: 10.2-12.8 vs 6.0 days, 50 95%CI: 5.6 - 6.3) and higher median carriage density (622 genome equivalents per millilitre, 95%CI: 51 507-714 vs 389, 95%CI: 311.1-435.5) were estimated in HIV-infected vs HIV-uninfected adults. The 52 use of ART and antibiotics substantially reduced carriage duration in all age groups, and acquisition 53 rates increased with household size. Although South African HIV-infected adults on ART have longer 54 carriage duration and density than their HIV-uninfected counterparts, they show similar patterns of 55 pneumococcal acquisition and onward transmission.

57 Author summary

58 We assessed the contribution of HIV-infected adults to household pneumococcal transmission by 59 applying a hidden Markov model to pneumococcal cohort data comprising 115,595 nasopharyngeal 60 samples from 1,684 individuals in rural and urban settings in South Africa. We estimated 14.4% of 61 sample misclassifications (false negatives), representing 85.6% sensitivity of a test that was used to 62 detect pneumococcus. Pneumococcal carriage prevalence and acquisition rates, and average duration 63 were usually higher in younger or older children than adults. The use of ART and antibiotics reduced 64 the average carriage duration across all age and HIV groups, and carriage acquisition risks increased 65 in larger household sizes. Despite the longer average carriage duration and higher median carriage 66 density in HIV-infected than HIV-uninfected adults, we found similar carriage acquisition and 67 onward transmission risks in the dual groups. These findings suggest that vaccinating HIV-infected 68 adults on ART with PCV would reduce their risk for pneumococcal disease but may add little to the 69 indirect protection against carriage of the rest of the population.

71 Introduction

72	Streptococcus pneumoniae (pneumococcus) caused an estimated 3.7 million cases of invasive
73	pneumococcal disease (IPD) and 317,300 deaths in children <5 years-old, globally in 2015 [1,2].
74	While severe disease is largely concentrated in young children and older adults, human
75	immunodeficiency virus (HIV)-infected adults are also at an increased risk of both colonisation and
76	IPD [3–7]. HIV affects the T and B cell function, resulting in impaired responses to control
77	pneumococcal carriage at mucosal level [8–10]. Although the universal scale-up of antiretroviral
78	therapy (ART) [11,12] has successfully reduced IPD risk in HIV-infected adults [13,14], the IPD risk
79	remains elevated if compared to HIV-uninfected adults [5,6]. ART partially reconstitutes mucosal
80	immunity by increasing B and T cell quantity and functionality [8,15], but deficiencies in humoral
81	mucosal response due to depleted or persistent defects in memory cell function persist after ART
82	initiation [16–18].
83	
84	Despite mature pneumococcal conjugate vaccine (PCV) infant immunisation programmes, continued
85	circulation of vaccine preventable serotypes in adults has been observed throughout Africa [19-25].
86	In some countries, such as Malawi, Mozambique, and Kenya, this intersects with areas of high HIV
87	prevalence. Adult HIV prevalence in Africa remains high [26] as a consequence of improved survival
88	with ART use [11,12] and persistently high HIV incidence [27], thus the high risk of pneumococcal
89	carriage and IPD in HIV-infected adults in Africa remains a concern.
90	
91	Vaccination of African HIV-infected adults with PCV, similar to the recommendations in many high-
92	income countries, may not only reduce their disease burden but also vaccine serotype pneumococcal
93	acquisition and hence onward transmission and may thus benefit non-vaccinated populations [28]. We
94	hypothesised that children living with HIV-infected adults have higher rates of pneumococcal carriage
95	acquisition due to increased exposure from frequently colonised HIV-infected adults who usually

- adults contribute more to pneumococcal transmission within the household than their HIV-uninfected
- 98 counterparts.
- 99

100 Methods

101 **Data description**

- 102 The temporal dynamics of pneumococcal colonisation were observed in a cohort study (Prospective
- 103 Household Observational Cohort Study of Influenza, Respiratory Syncytial Virus and Other
- 104 Respiratory Pathogens Community Burden and Transmission Dynamics PHIRST) conducted
- 105 between 2016 and 2018 in a rural (Agincourt) and an urban (Klerksdorp) community in South Africa.
- 106 Households were randomly selected, and were eligible for the study if they had \geq 3 household
- 107 members and the household members resided in the household for ≥ 1 year prior to study
- 108 commencement, had no plan to relocate during study duration, and consented to participate in the
- 109 study. Also, enrolment ensured that more than half of the households included at least one child aged
- 110 <5 years, and a new cohort was enrolled every study year [29,30].
- 111
- 112 A total of 1,684 individuals from 327 households were enrolled and followed up from May to October
- 113 in 2016 and January to October in 2017 and 2018. The median household size was 5 (interquartile
- 114 range 4-7). Nasopharyngeal (NP) swabs were taken twice weekly, resulting in 115,595 total NP
- samples from 1,684 individuals [28]. The swabs were tested for the presence of pneumococci using
- 116 real-time quantitative polymerase chain reaction (qPCR), targeting the autolysin (*lytA*) gene [31].
- 117 Serotyping was not performed. On enrolment, all household members were tested for HIV infection
- 118 and the demographic characteristics of the study participants was recorded.

119

120 Modelling framework

121 We used a continuous time, time homogeneous, hidden Markov model (HMM) which assumed a

- 122 Susceptible Infected Susceptible (SIS) framework [32–38], to fit to individual level trajectories of
- 123 colonisation during the study period. An individual can be either infected (I) and currently carrying

124 pneumococci or be susceptible (S). Thus, the model can be described by transition intensities between 125 S and I for acquisition (q_{12}) and clearance (q_{21}) in the transition intensity matrix Q = $\begin{pmatrix} -q_{12} & q_{12} \\ q_{21} & -q_{21} \end{pmatrix}$. Covariates for acquisition and clearance rates are incorporated via a proportional 126 hazard. To obtain the transition probabilities, matrix $P = \begin{pmatrix} 1 - p_{12} & p_{12} \\ p_{21} & 1 - p_{21} \end{pmatrix}$ is defined and 127 explicitly calculated through matrix exponential, $P = \exp(Q(t))$, where p_{12} is the probability of 128 129 being in state 2 (I) at time t > 0, given that the previous state was 1 (S). A more detailed description 130 of the Markov transition process is provided in the Supplement. 131 132 In the hidden Markov modelling (HMM) framework [34,39–44], the states S and I of the Markov 133 Chain $(X_i(t))$ for individual i at time t are not observed directly, but approximated by the results of a 134 NP swab. The link between the modelled, true infection status and observed pneumococcal carriage 135 states in the model $(Y_i(t))$ is governed by emission probabilities conditional on the unobserved state. 136 We assumed 100% specificity of the NP swab and the PCR (no false positive) while estimating the 137 proportion of false negative results (e) probabilistically (observed vs hidden/truth states). Hence, the emission matrix is given as $E = \begin{pmatrix} 1 & 0 \\ e_{21} & 1 - e_{21} \end{pmatrix}$ where $e_{21} = \Pr(Y_i(t) = 1 \mid X_i(t) = 2)$. 138 139

We assumed that the observed states are conditionally independent given the values of the unobserved states and that the future Markov chain is independent of its history beyond the current state (Markov property) (Fig 1). Thus, the likelihood is the product of the emission probability density and the transition probability of hidden Markov chain summed over all possible paths of the hidden states (explicitly defined in the Supplement).

145

146 Our model assumed that carriage acquisition at the current observation point was a function of

147 individual age group (younger child aged <5 years, older child aged 5-17 years, or adult aged ≥ 18

148 years), HIV status (infected or uninfected), number of HIV-infected adult(s) in the household, place

149 of carriage exposure (household or community), and household size. Carriage duration was modified

150	by individual age, HIV status, ART status, and antibiotic use. The place of carriage exposure is
151	generally unknown without fine-scale serotype data. Crudely, we assumed that if a household member
152	is currently infected while all other household members were susceptible at the last observation point,
153	then current carriage acquisition of that member was attributable to community transmission [34].
154	Otherwise we assumed that the transmission was from within the same household (Fig 1).
155	
156	Model fit, convergence and prediction
157	The model was fitted to longitudinal data of pneumococcal carriage dynamics in a maximum
158	likelihood framework using Bound Optimisation By Quadratic Approximation optim algorithm
159	facilitated by msm R package [34,45]. To ascertain convergence of the model, we purposefully
160	selected five unique pairs of initial transition intensities $\{S, I\}$ for the Q matrix, then refitted the
161	model five times, each time starting a Markov chain with a unique dyad and iterating 1,000 times to
162	obtain similar final transition intensities and -2log-likelihood. Model predictions were assessed by
163	comparing infection and susceptibility prevalence in 14-day intervals for the observed data to the
164	fitted values. (S1 Fig) [34].

165

166 **Decoding the underlying carriage sequence**

After fitting the HMM, a Viterbi algorithm with the msm function was used to recursively construct the sequence of pneumococcal carriage with the highest probability through the hidden states [46]. The probability of each hidden state at each observation point, conditionally on all the data was computed using Baum-Welch forward/backward algorithm. Thus, an overall misclassification probability of the observed states given the hidden states was computed. Model estimates of carriage transition intensity and probability were adjusted for misclassification probability (S2 Fig).

173

174 Sensitivity analysis

175 In a sensitivity analysis, three alternative and potentially more parsimonious models were fitted176 separately to the data. Fits of these models were compared to the main model using the on Akaike

177	Information Criterion (AIC) [47] and checked whether they yielded qualitatively different results to
178	the main model. Each of the four fitted models assumed the same number of covariates to modify
179	carriage acquisition intensity but varying number of covariates assumed to modify carriage duration.
180	Potential modifiers of carriage duration included age and HIV status for model 1; age, HIV status and
181	antibiotic use for model 2; age, HIV status and viral load based ART status for model 3; and age, HIV
182	status, antibiotic use and viral load based ART status for main model 4 (S1 Table).
183	
184	Further, we examined the impact of alternative stratification of covariates on the changes in carriage
185	transition probabilities: (i) while the main analysis estimated age- and HIV-stratified carriage
186	acquisition rates comparing households with ≥ 1 HIV-infected adult(s) versus households without
187	HIV-infected adults, in the sensitivity analysis, we estimated age- and HIV-stratified carriage
188	acquisition rates comparing households with 0,1, 2, 3, 4 and 5 HIV-infected adult(s) and (ii) rather
189	than assuming time-homogeneous intensities throughout the study period, we relaxed this assumption
190	by fitting a time-inhomogeneous model with piecewise follow-up periods; 0-99 days, 100-139, 140-
191	199, 200-219 and 220-289 (S3 Fig).
192	
193	Statistical significance was set at <0.05. All analyses were conducted in R v3.5.0 [34,48] and are
194	available via https://github.com/deusthindwa/hmm.pneumococcus.hiv.south-africa.
195	
196	Ethical approval
197	The longitudinal pneumococcal carriage data described in this study were obtained from consenting
198	South African children and adults as part of the PHIRST study. The use of data was granted by the
199	University of Witwatersrand, Human Research Ethics Committee (HREC) and the Protocol Review
200	Committee (PRC) under approval #150808, the US CDC's Institutional Review Board relied on the

- 201 local review (#6840), and the London School of Hygiene & Tropical Medicine Observational
- 202 Research Ethics Committee under approval #17902.

204 **Results**

205 **Descriptive analysis**

A total of 327 households were recruited in the PHIRST study of which 166 (50.8%) had at least one

- 207 member living with HIV infection. At enrolment, of 1,684 individuals included in the study, 279
- 208 (16.6%) were younger children aged less than 5 years old of whom 4 (1.5%) were HIV-infected, and
- 209 679 (40.3%) were older children aged between 5-17 years old of whom 31 (4.7%) were HIV-infected.
- Among the 726 (43.1%) study participants aged 18 years or older ("adults"), 214 (30.4%) were HIV-
- 211 infected, and 505 (69.6%) were females. Among those HIV-infected adults, 196 (86.7%) self-reported
- to be on ART, although only 151 (79.5%) had CD4+ cell count of more than 350. Most adults were
- 213 non-smokers (69.6%) and did not regularly consume alcohol (57.4%). A similar proportion of
- children lived in households with (50.6%) and without (49.4%) at least one HIV-infected adult.
- 215 Among 231 younger children with vaccine information available, 227 (98.3%) received first PCV
- dose at 6 weeks, 225 (97.4%) second dose at 14 weeks and 216 (93.5%) third dose at 9 months of age

217 (Table 1).

218

219 Carriage prevalence and density

220 Among HIV-uninfected participants, observed pneumococcal carriage prevalence was higher in 221 younger children (range across visits: 56.9-80.5%) than older children (31.7-50.0%) and was lowest 222 in adults (11.5-23.5%) (Fig 2A). Among HIV-infected participants, pneumococcal carriage 223 prevalence fluctuated in younger children (0-100%), in older children (30-77%), and in adults (14-224 34%) (Fig 2A). The likelihood of detecting pneumococcal carriage during visits was higher for 225 children than adults and for HIV-infected younger children or older children or adults than their HIV-226 uninfected counterparts (Fig 2B). Carriage prevalence among younger HIV-uninfected children was 227 lower in households with less than 6 members (65.5%, 95%CI: 64.5-66.5) than in households with 6-228 10 (72.5%, 95%CI: 71.5-73.5) or household more than 10 members (85.6%, 95%CI: 82.4-88.8) but it 229 was similar in HIV-infected children across household size groups (Fig 2C). Carriage prevalence 230 fluctuated across visits by HIV-infection and sex in adults, with similar ranges between HIV-

231	uninfected male adults 10.8-25.3% and HIV-uninfected female adults 10.2-24.0%, and between HIV-
232	infected male adults 6.3-40.7% and HIV-infected female adults 12.3-34.6% (S5A Fig).
233	
234	Median pneumococcal carriage density, in genome equivalents per millilitre (GE/ml), was
235	significantly higher in younger children (24,341, 95%CI: 22,638-26,122) than older children (3,490,
236	95%CI: 3,168-3,754) or adults (476, 95%CI: 429-522). Also, median carriage density was higher in
237	HIV-infected than HIV-uninfected older children (11,156, 95%CI: 8,681-13,948 vs 3,221, 95%CI:
238	2,911-3,472) or adults (622, 95%CI: 507-714 vs 389, 95%CI: 311-435), and not in younger children
239	(33,050, 95%CI: 22,690-42,293 vs 24,124, 95%CI: 22,547-25,838) (Fig 2D). Conversely, median
240	carriage density was similar between those not on ART compared to those on ART in older children
241	(9,624, 95%CI: 5,289-11,843 vs 8,818, 95%CI: 5,102-12,720) or adults (861, 95%CI: 508-1,001 vs
242	499, 95%CI: 382-586), and not in younger children (25,430, 95%CI: 13,138-40,245 vs 91,566,
243	95%CI: 43,355-265,628) (Fig 2E). About 14.4%, 95%CI: 13.7-15.0 of negative NP swab results were
244	estimated probabilistically to be false negatives.
245	
246	Pneumococcal carriage acquisition
247	Overall, pneumococcal carriage acquisition was higher in older children (1.15, 95%CI: 1.08-1.23) and
248	younger children (1.52, 95%CI: 1.38-1.68) than adults. Acquisition of carriage was more frequently
249	observed when at least another household member was infected half a week before (and hence

attributed to household transmission) than in previously uninfected households (1.80, 95%CI: 1.68-

251 1.93). Irrespective of age and HIV status, acquisition rates from within the household increased with

household size; by 1.05 (95%CI: 1.00-1.10) in households with 6-10 members and by 1.41 (95%CI:

1.24-1.60) in households with 11 or more members compared to households with less than 6

254 members. However, within household carriage acquisition rates in children, irrespective of age group

and HIV status, were not higher in the households with at least one HIV-infected adult (0.95, 95%CI:

256 0.91-1.01) (Table 2, Fig 3). In addition, daily carriage acquisition rates in HIV-uninfected younger

257	children did	d not significantly	v varv between	households with I	HIV-infected f	female adults ((0.1)
231		u not significanti		nouscholus with I		cillate adults i	ιυ.

- 258 95%CI: 0.12-0.17) and those with HIV-infected male adults (0.13, 95%CI: 0.11-0.15) (S5 Fig).
- 259
- 260 We estimated 3.8 carriage acquisition episodes per year, (95%CI: 3.4-4.2) for HIV-infected younger
- children, 5.9 (95%CI: 5.4-6.3) for HIV-uninfected younger children, 7.4 (95%CI: 6.7-8.1) for HIV-
- 262 infected older children and 10.6 (95%CI: 10.2-11.0) for HIV-uninfected older children from
- 263 households with at least one HIV-infected adult, and these were similar to their counterparts from
- 264 households without HIV-infected adults (3.8, 95%CI: 3.3-4.2 and 5.8, 95%CI: 5.4-6.3, and 7.3,
- 265 95%CI: 6.6-8.0 and 10.3, 95%CI: 9.9-10.8, respectively) (Fig 3, S2 Table).
- 266

267 Pneumococcal carriage duration

268 The average duration of pneumococcal carriage was highest in HIV-infected and HIV-uninfected

- 269 younger children (107.9 days, 95%CI: 92.1-124.7 and 56.3 days, 95%CI: 51.1-62.1) followed by
- HIV-infected and HIV-uninfected older children (33.9 days, 95%CI: 29.9-38.6 and 17.9 days, 95%CI:
- 271 16.8-18.5), and HIV-infected and HIV-uninfected adults (11.4 days, 95%CI: 10.2-12.8 and 6.0 days,
- 272 95%CI: 5.6-6.3) (Fig 4C, Fig 4D, and S3 Table).
- 273

274 Pneumococcal carriage cleared slower in older children (Hazard Ratio [HR]: 0.34, 95%CI: 0.31-0.36)

and younger children (HR: 0.10, 95%CI: 0.09-0.12) when compared to adults. Carriage clearance was

- slower in HIV-infected than in HIV-uninfected individuals (HR: 0.52, 95%CI: 0.46-0.59), and faster
- in HIV-infected individuals with successfully suppressed viral load than in those without successful
- viral suppression (HR: 1.29, 95%CI: 1.13-1.47) (Fig 4B, Table 2). Antibiotic use may have
- accelerated pneumococcal clearance; however, the effect was not statistically significant (HR: 1.47,
- 280 95%CI: 0.67-3.25) (Fig 4A, Table 2).
- 281

282 Sensitivity analysis

In the sensitivity analysis, a model that included age, HIV status, antibiotic use, and ART status as potential modifiers for pneumococcal carriage duration had the lowest AIC score as well as for including both antibiotic use and ART status (S1 Table). Increasing the number of HIV-infected adults within household to 1, 2, 3, 4, and 5 resulted in similar estimates of pneumococcal carriage acquisition in younger or older children (S3A Fig). Our results were also robust when instead of assuming a time homogeneous hidden Markov model, we allowed for the estimation of time varying transition probabilities (S3B Fig)

290

291 Discussion

292 We used a HMM to better understand pneumococcal carriage dynamics, and the role of HIV-infected 293 adults in it, using data from a densely sampled longitudinal South African cohort using data from 294 115,595 nasopharyngeal swabs. We estimated that children have higher acquisition rates and duration 295 of carriage than adults, and that, within a household, HIV-infected adults are not more likely to 296 transmit pneumococci to children than HIV-uninfected adults. Pneumococcal acquisition events increased with larger household size irrespective of age and HIV status. Although ART use reduced 297 298 pneumococcal carriage duration in HIV-infected children and adults, they still carry pneumococci for 299 longer than their HIV-uninfected counterparts.

300

Higher household acquisition rates in children than adults have been reported previously [32,49–53],
although not consistently across studies [35,54]. This may reflect setting-specific population mixing
behaviour and immunisation levels. Similarly, and for the first time in the presence of a mature infant
PCV routine vaccination programme, we find that children both have higher acquisition rates than
adults and carry pneumococci for longer, making them a likely key source for pneumococcal
transmission in and beyond the household [55,56].

308 We postulated that HIV-infected adults were more likely to carry pneumococci and may have higher 309 carriage density which individually or in combination may increase their risk for pneumococcal transmission compared to HIV-uninfected adults. Prior to infant PCV introduction, a study in Malawi 310 311 showed that HIV-infected adults on ART had higher carriage prevalence than those not on ART [5], 312 and two studies in South Africa also found that HIV-infected adults (mothers) had higher carriage 313 prevalence than their HIV-uninfected counterparts, irrespective of ART status [32,49]. In addition, 314 HIV-infected adults (mothers) were found to transmit pneumococci to their children more often than 315 HIV-uninfected peers [32]. We generated additional evidence showing that, in the PCV era, carriage 316 prevalence is slightly increased in HIV-infected adults on ART compared to HIV-uninfected adults as 317 a result of reduced carriage clearance rates. We also show that median carriage density is higher in 318 HIV-infected than HIV-uninfected adults. However, we find no evidence that carriage density is 319 modified by ART status in HIV-infected adults (Fig 2). Further research may need to investigate 320 whether differential effects of ART on pneumococcal carriage density in adults by country may be 321 driven by types of ART regimens used.

322

323 Furthermore, our model estimates that the presence of an HIV-infected adult in the household does 324 not increase the risk for pneumococcal carriage acquisition in co-habiting children. Although it is 325 possible that there may have been other HIV-infected adults within households who were not enrolled 326 into the study, it is unlikely this would alter the results given the insensitive acquisition estimates with 327 increasing number of HIV-infected adults within household (S3A Fig). These findings support the 328 notion that ART largely, but not completely, reconstitutes the anti-pneumococcal mucosal immune 329 response in HIV-infected adults [8]. This would imply that HIV-infected adults do not contribute 330 disproportionally to pneumococcal transmission when on ART and hence that their vaccination is 331 unlikely to substantially add to the herd protection already induced by the childhood immunisation 332 programme although vaccination will provide direct protection against IPD in HIV-infected adults. 333

Our observation of increasing pneumococcal carriage acquisition rates with higher household size has
also been reported previously [36] and suggests density dependent transmission in the household [57].

336 In line with evidence before infant PCV introduction [32,36], we find that pneumococcal carriage 337 acquisition probabilities from the community were higher in children than in adults irrespective of 338 HIV status, likely in part due to frequent effective contacts among playschool children [49,58] and 339 immature immunity in children relatively to adults. We also estimate that children were twice as 340 likely to get infected from within the household than from the community. However, we base this 341 inference on the identified pneumococcal carriage in a household member at the previous visit. 342 343 In the absence of serotyping of the pneumococcal isolates, our inferences may be prone to 344 overestimation within household transmission by linking family members who in fact were infected 345 with different pneumococcal serotypes. Similarly, serotyping would enhance our ability to 346 differentiate a single and long carriage episode from almost immediate re-acquisition or the clearance 347 of the dominant serotype while the previously subdominant serotype persists. This may have led to an 348 overestimation of carriage duration and underestimated clearance rates. However, the mean carriage 349 duration of 56 days (51-62) in HIV-uninfected children estimated in this study aligns with studies that 350 used serotype data [32,35,49,59]. While both the estimates for duration of carriage and the 351 contribution of household transmission may be somewhat exaggerated, the lack of serotyping should 352 not have affected our primary outcome, the relative contribution of HIV infected adults to 353 pneumococcal transmission. 354 355 The use of ART, as inferred from measured viral load in study participants, reduced pneumococcal 356 carriage duration by 22% compared to no ART use within each age group of HIV-infected 357 participants. However, mean pneumococcal carriage duration remained slightly higher than their 358 HIV-uninfected counterparts (Fig 4). Our model also estimated the sensitivity of the swabbing and 359 qPCR testing regime for the detection of pneumococcal carriage. We estimate that about 1 in 7 swabs 360 were misclassified as pneumococcal negative. False negatives might have arisen as a result of the 361 sampling technique or if samples contained insufficient quantities of bacteria to successfully amplify 362 and detect [58]. We assumed 100% specificity of an assay targeting the autolysin gene as the

- 363 probability of false positives is seemingly very low [31,59]. Our estimated misclassification
- 364 probability in this study is within 10-20% range of values that were reported elsewhere [59,60].
- 365
- 366 In conclusion, we used one of the most densely sampled longitudinal pneumococcal carriage studies
- 367 to infer the role of HIV-infected adults in pneumococcal transmission in the PCV and ART era. We
- 368 find that the transmission risk from HIV-infected adults largely aligns with that of their uninfected
- 369 counterpart. This implies that PCV use in HIV-infected adults who have access to ART would reduce
- 370 their risk for pneumococcal disease but may have little added benefit over vaccinating other adults to
- the indirect protection against carriage of the rest of the population.

373

374 **Declaration**

375 Funding

This research was commissioned by the National Institute for Health Research (NIHR) Global Health
Research Unit on Mucosal Pathogens under the UK Government. PHIRST study was funded by a
cooperative agreement with the United States Centers for Disease Control and Prevention (grant
number 1U01IP001048) and the Bill and Melinda Gates Foundation (Grant number: OPP1164778).

380

381 Acknowledgement

382 DT, OJ are supported by the National Institute for Health Research (NIHR) Global Health Research 383 Unit on Mucosal Pathogens (MPRU) using UK aid from the UK Government (16/136/46). AP is 384 supported by the Bill and Melinda Gates Foundation. SF is supported by a Sir Henry Dale Fellowship 385 jointly funded by the Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z). CC and 386 AvG receive grant support through their institution from Sanofi Pasteur. The funders had no 387 involvement in the study design; collection, analysis and interpretation of data; writing of the report; 388 or decision to submit the article for publication. Members of the Prospective Household Observational 389 Cohort Study of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens Community 390 Burden and Transmission Dynamics (PHIRST) have played a role of funding-acquisition and 391 administration. The following are members of the PHIRST group: Centre for Respiratory Diseases 392 and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory 393 Service, Johannesburg, South Africa (Amelia Buys, Lorens Maake, Florette Treurnicht, Orienka 394 Hellferscee, Thulisa Mkhencele); Environment and Health Research Unit, South African Medical 395 Research Council, Johannesburg, South Africa (Angie Mathee); Unit for Environmental Science and 396 Management, School of Geo- and Spatial Science, North-West University, Potchefstroom, South 397 Africa (Brigitte Language, Stuart Piketh); School of Public Health, Faculty of Health Sciences, 398 University of the Witwatersrand, Johannesburg (Lorens Maake, Floidy Wafawanaka, Ryan G 399 Wagner, F. Xavier Gómes-Olivé, Kathleen Kahn); Perinatal HIV Research Unit, MRC Soweto

400	Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand,
401	Johannesburg, South Africa (Katlego Mothlaoleng, Limakatso Lebina, Neil A Martinson); Johns
402	Hopkins University Center for TB Research, Baltimore, Maryland, United States of America (Neil A
403	Martinson). We are grateful to all individuals who participated in the PHIRST study. We also thank
404	all community leaders from Agincourt Klerksdorp for allowing us to conduct PHIRST study in these
405	areas.
406	
407	Author contribution
408	Conceptualization: DT, SF, NF; Methodology: DT, SF, AP; Writing-Original Draft: DT; Writing-
409	Review and Editing: DT, NW, AP, CM, JO, ST, JM, MM, JK, AvG, NF, CC, SF; Funding-
410	Acquisition: DT, CC, AvG. All authors read and approved the final manuscript.
411	
412	Competing interests
413	The authors declare that they have no known competing financial interests or personal relationships
414	that could have appeared to influence the work reported in this paper.
415	
416	Disclaimer
417	The findings and conclusions in this publication are those of the authors and do not necessarily
418	represent the official position of the United States Centers for Disease Control and Prevention, the
419	NIHR or the Department of Health and Social Care.

421 **Reference**

- O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of
 disease caused by Streptococcus pneumoniae in children younger than 5 years: global
 estimates. The Lancet. 2009;374: 893–902. doi:10.1016/S0140-6736(09)61204-6
- Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of
 Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in
 the era of conjugate vaccines: global, regional, and national estimates for 2000–15.
 The Lancet Global Health. 2018;6: e744–e757. doi:10.1016/S2214-109X(18)30247-X
- 429 3. van Aalst M, Lötsch F, Spijker R, van der Meer JTM, Langendam MW, Goorhuis A, et al.
 430 Incidence of invasive pneumococcal disease in immunocompromised patients: A
 431 systematic review and meta-analysis. Travel Medicine and Infectious Disease. 2018;24:
 432 89–100. doi:10.1016/j.tmaid.2018.05.016
- 4. Corcoran M, Vickers I, Mereckiene J, Murchan S, Cotter S, Fitzgerald M, et al. The
 epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has
 there been a herd effect? Epidemiology & Infection. 2017;145: 2390–2399.
 doi:10.1017/S0950268817001194
- 437 5. Heinsbroek E, Tafatatha T, Phiri A, Ngwira B, Crampin A, Read J, et al. Persisting high
 438 prevalence of pneumococcal carriage among HIV-infected adults receiving
 439 antiretroviral therapy in Malawi. Aids. 2015;29: 1837–1844.
 440 doi:10.1097/QAD.0000000000755
- 441
 6. Nunes MC, Gottberg A von, Gouveia L de, Cohen C, Kuwanda L, Karstaedt AS, et al.
 442
 443 Persistent High Burden of Invasive Pneumococcal Disease in South African HIV-Infected
 443 Adults in the Era of an Antiretroviral Treatment Program. PLOS ONE. 2011;6: e27929.
 444 doi:10.1371/journal.pone.0027929
- Gill CJ, Mwanakasale V, Fox MP, Chilengi R, Tembo M, Nsofwa M, et al. Impact of
 Human Immunodeficiency Virus Infection on Streptococcus pneumoniae Colonization
 and Seroepidemiology among Zambian Women. J Infect Dis. Oxford Academic;
 2008;197: 1000–1005. doi:10.1086/528806
- 8. Zhang L, Li Z, Wan Z, Kilby A, Kilby JM, Jiang W. Humoral immune responses to
 Streptococcus pneumoniae in the setting of HIV-1 infection. Vaccine. 2015;33: 4430–
 4436. doi:10.1016/j.vaccine.2015.06.077
- 452 9. Jochems SP, Weiser JN, Malley R, Ferreira DM. The immunological mechanisms that
 453 control pneumococcal carriage. PLOS Pathogens. 2017;13: e1006665.
 454 doi:10.1371/journal.ppat.1006665
- 455 10. Iwajomo OH, Finn A, Ogunniyi AD, Williams NA, Heyderman RS. Impairment of
 456 Pneumococcal Antigen Specific Isotype-Switched Igg Memory B-Cell Immunity in HIV
 457 Infected Malawian Adults. PLOS ONE. 2013;8: e78592.
- 458 doi:10.1371/journal.pone.0078592

- 459 11. Harries AD, Ford N, Jahn A, Schouten EJ, Libamba E, Chimbwandira F, et al. Act local,
 460 think global: how the Malawi experience of scaling up antiretroviral treatment has
 461 informed global policy. BMC Public Health. 2016;16: 938. doi:10.1186/s12889-016462 3620-x
- 463 12. Jahn A, Harries AD, Schouten EJ, Libamba E, Ford N, Maher D, et al. Scaling-up
 464 antiretroviral therapy in Malawi. Bulletin of the World Health Organization. 2016;94:
 465 772–776. doi:10.2471/BLT.15.166074
- 466
 467
 468
 468
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
- 470
 470 14. Everett DB, Mukaka M, Denis B, Gordon SB, Carrol ED, Oosterhout JJ van, et al. Ten
 471 Years of Surveillance for Invasive Streptococcus pneumoniae during the Era of
 472 Antiretroviral Scale-Up and Cotrimoxazole Prophylaxis in Malawi. PLOS ONE. 2011;6:
 473 e17765. doi:10.1371/journal.pone.0017765
- 474 15. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate
 475 vaccine in HIV-infected individuals. Human Vaccines & Immunotherapeutics. 2012;8:
 476 161–173. doi:10.4161/hv.18432
- 477 16. Eley B. Immunization in Patients with HIV Infection. Drugs. 2008;68: 1473–1481.
 478 doi:10.2165/00003495-200868110-00001
- 479 17. De Milito A, Mörch C, Sönnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in
 480 HIV-1 infection. AIDS. 2001;15: 957.
- 18. Madhi SA, Kuwanda L, Cutland C, Holm A, Käyhty H, Klugman KP. Quantitative and
 Qualitative Antibody Response to Pneumococcal Conjugate Vaccine Among African
 Human Immunodeficiency Virus-Infected and Uninfected Children. The Pediatric
 Infectious Disease Journal. 2005;24: 410. doi:10.1097/01.inf.0000160942.84169.14
- 485
 485
 486
 486
 487
 487
 488
 488
 489
 489
 480
 480
 480
 480
 481
 481
 482
 483
 484
 484
 484
 485
 485
 486
 486
 486
 487
 487
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 489
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
 480
- 20. Lourenço J, Obolski U, Swarthout TD, Gori A, Bar-Zeev N, Everett D, et al. Determinants
 of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi: a
 modelling study. BMC Medicine. 2019;17. doi:10.1186/s12916-019-1450-2
- 492 21. Heinsbroek E, Tafatatha T, Phiri A, Swarthout TD, Alaerts M, Crampin AC, et al.
 493 Pneumococcal carriage in households in Karonga District, Malawi, before and after
 494 introduction of 13-valent pneumococcal conjugate vaccination. Vaccine. 2018;36:
 495 7369–7376. doi:10.1016/j.vaccine.2018.10.021

496
422. Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, et al. Effect of ten-valent
497 pneumococcal conjugate vaccine on invasive pneumococcal disease and
498 nasopharyngeal carriage in Kenya: a longitudinal surveillance study. The Lancet. 2019;
499 doi:10.1016/S0140-6736(18)33005-8

- Sigaúque B, Moiane B, Massora S, Pimenta F, Verani JR, Mucavele H, et al. Early Declines
 in Vaccine Type Pneumococcal Carriage in Children Less Than 5 Years Old After
- 502 Introduction of 10-valent Pneumococcal Conjugate Vaccine in Mozambique. The 503 Pediatric Infectious Disease Journal. 2018;37: 1054.
- 504 doi:10.1097/INF.00000000002134

24. Usuf E, Bottomley C, Bojang E, Cox I, Bojang A, Gladstone R, et al. Persistence of
Nasopharyngeal Pneumococcal Vaccine Serotypes and Increase of Nonvaccine
Serotypes Among Vaccinated Infants and Their Mothers 5 Years After Introduction of
Pneumococcal Conjugate Vaccine 13 in The Gambia. Clin Infect Dis. 2019;68: 1512–
1521. doi:10.1093/cid/ciy726

- 510 25. Klugman KP, Rodgers GL. Population versus individual protection by pneumococcal
 511 conjugate vaccination. The Lancet. 2019;393: 2102–2104. doi:10.1016/S0140512 6736(19)30039-X
- 513 26. Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR, et al. Mapping
 514 HIV prevalence in sub-Saharan Africa between 2000 and 2017. Nature. 2019;570: 189.
 515 doi:10.1038/s41586-019-1200-9
- 516 27. UNAIDS. Global HIV & AIDS databook [Internet]. Geneva, Switzerland: Joint United
 517 Nations Programme on HIV/AIDS; 2017 pp. 1–248. Available:
- https://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_
 en.pdf
- 520 28. Thindwa D, Pinsent A, Ojal J, Gallagher KE, French N, Flasche S. Vaccine strategies to
 521 reduce the burden of pneumococcal disease in HIV-infected adults in Africa. Expert
 522 Review of Vaccines. Taylor & Francis; 2020;0: 1–8.
- 523 doi:10.1080/14760584.2020.1843435
- 29. Cohen C, McMorrow M, Martinson NA, Kahn K, Treurnicht FK, Moyes J, et al. Cohort
 Profile: a Prospective Household cohort study of Influenza, Respiratory Syncytial virus,
 and other respiratory pathogens community burden and Transmission dynamics in
 South Africa (PHIRST), 2016-2018. medRxiv. Cold Spring Harbor Laboratory Press; 2021;
 2021.01.06.21249313. doi:10.1101/2021.01.06.21249313
- 30. Cohen C, Kleynhans J, Moyes J, McMorrow ML, Treurnicht FK, Hellferscee O, et al.
 Asymptomatic transmission and high community burden of seasonal influenza in an
 urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort
 study. The Lancet Global Health. 2021;9: e863–e874. doi:10.1016/S2214109X(21)00141-8
- 53431. Blaschke AJ. Interpreting Assays for the Detection of Streptococcus pneumoniae. Clin535Infect Dis. Oxford Academic; 2011;52: S331–S337. doi:10.1093/cid/cir048

- 536 32. Shiri T, Auranen K, Nunes MC, Adrian PV, van Niekerk N, de Gouveia L, et al. Dynamics of 537 Pneumococcal Transmission in Vaccine-Naïve Children and Their HIV-infected or HIV-538 uninfected Mothers During the First 2 Years of Life. Am J Epidemiol. 2013;178: 1629– 1637. doi:10.1093/aje/kwt200 539 540 33. Cox DR, Miller HD. The Theory of Stochastic Processes. CRC Press; 1977. 541 34. Jackson C. Multi-State Models for Panel Data: The msm Package for R. Journal of 542 Statistical Software. 2011;38: 1-28. doi:10.18637/jss.v038.i08 543 35. Lipsitch M, Abdullahi O, D'Amour A, Xie W, Weinberger D, Tchetgen ET, et al. Estimating 544 Rates of Carriage Acquisition and Clearance and Competitive Ability for Pneumococcal 545 Serotypes in Kenya With a Markov Transition Model. Epidemiology. 2012;23: 510–519. 546 doi:10.1097/EDE.0b013e31824f2f32 547 36. Melegaro A, Gay NJ, Medley GF. Estimating the transmission parameters of 548 pneumococcal carriage in households. Epidemiol Infect. 2004;132: 433-441.
- 37. Melegaro A, Choi Y, Pebody R, Gay N. Pneumococcal Carriage in United Kingdom
 Families: Estimating Serotype-specific Transmission Parameters from Longitudinal
 Data. Am J Epidemiol. 2007;166: 228–235. doi:10.1093/aje/kwm076
- 38. Jones E, Epstein D, García-Mochón L. A Procedure for Deriving Formulas to Convert
 Transition Rates to Probabilities for Multistate Markov Models. Medical Decision
 Making. 2017;37: 779–789. doi:10.1177/0272989X17696997
- 39. Jackson CH, Sharples LD. Hidden Markov models for the onset and progression of
 bronchiolitis obliterans syndrome in lung transplant recipients. Statistics in Medicine.
 2002;21: 113–128. doi:10.1002/sim.886
- 40. Jackson CH, Sharples LD, Thompson SG, Duffy SW, Couto E. Multistate Markov models
 for disease progression with classification error. Journal of the Royal Statistical Society:
 Series D (The Statistician). 2003;52: 193–209. doi:10.1111/1467-9884.00351
- 41. Bureau A, Shiboski S, Hughes JP. Applications of continuous time hidden Markov models
 to the study of misclassified disease outcomes. Statistics in Medicine. 2003;22: 441–
 462. doi:10.1002/sim.1270
- 42. Cooper B, Lipsitch M. The analysis of hospital infection data using hidden Markov
 models. Biostatistics. 2004;5: 223–237. doi:10.1093/biostatistics/5.2.223
- 566 43. Satten GA, Longini IM. Markov Chains With Measurement Error: Estimating the `True'
 567 Course of a Marker of the Progression of Human Immunodeficiency Virus Disease.
 568 Journal of the Royal Statistical Society Series C (Applied Statistics). 1996;45: 275–309.
 569 doi:10.2307/2986089
- 44. McClintock BT, Langrock R, Gimenez O, Cam E, Borchers DL, Glennie R, et al. Uncovering
 ecological state dynamics with hidden Markov models. Ecology Letters. 2020;23: 1878–
 1903. doi:https://doi.org/10.1111/ele.13610

- 573 45. Powell MJD. The BOBYQA algorithm for bound constrained optimization without
- 574 derivatives. Cambridge; 2009. p. 39. Available:
- 575 http://www.damtp.cam.ac.uk/user/na/NA_papers/NA2009_06.pdf
- 46. Viterbi A. Error bounds for convolutional codes and an asymptotically optimum
 decoding algorithm. IEEE Transactions on Information Theory. 1967;13: 260–269.
 doi:10.1109/TIT.1967.1054010
- 579 47. Stone M. An Asymptotic Equivalence of Choice of Model by Cross-Validation and
 580 Akaike's Criterion. Journal of the Royal Statistical Society Series B (Methodological).
 581 1977;39: 44–47.
- 48. R Core Team (2018). R: A language and environment for statistical computing. R
 Foundation for Statistical Computing, Vienna, Austria. [Internet]. [cited 28 May 2019].
 Available: https://www.r-project.org/
- 49. Nunes MC, Shiri T, van Niekerk N, Cutland CL, Groome MJ, Koen A, et al. Acquisition of
 Streptococcus pneumoniae in Pneumococcal Conjugate Vaccine-naïve South African
 Children and Their Mothers. The Pediatric Infectious Disease Journal. 2013;32: e192.
 doi:10.1097/INF.0b013e31828683a3
- 50. Heinsbroek E, Tafatatha T, Chisambo C, Phiri A, Mwiba O, Ngwira B, et al. Pneumococcal
 Acquisition Among Infants Exposed to HIV in Rural Malawi: A Longitudinal Household
 Study. Am J Epidemiol. 2016;183: 70–78. doi:10.1093/aje/kwv134
- 592 51. Turner P, Turner C, Jankhot A, Helen N, Lee SJ, Day NP, et al. A Longitudinal Study of
 593 Streptococcus pneumoniae Carriage in a Cohort of Infants and Their Mothers on the
 594 Thailand-Myanmar Border. PLOS ONE. Public Library of Science; 2012;7: e38271.
 595 doi:10.1371/journal.pone.0038271
- 596 52. Hussain M, Melegaro A, Pebody RG, George R, Edmunds WJ, Talukdar R, et al. A
 597 longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in
 598 a UK setting. Epidemiology & Infection. 2005;133: 891–898.
 599 doi:10.1017/S0950268805004012
- 53. Althouse BM, Hammitt LL, Grant L, Wagner BG, Reid R, Larzelere-Hinton F, et al.
 Identifying transmission routes of *Streptococcus pneumoniae* and sources of
 acquisitions in high transmission communities. Epidemiology and Infection. 2017;145:
 2750–2758. doi:10.1017/S095026881700125X
- 54. Abdullahi O, Karani A, Tigoi CC, Mugo D, Kungu S, Wanjiru E, et al. Rates of Acquisition
 and Clearance of Pneumococcal Serotypes in the Nasopharynges of Children in Kilifi
 District, Kenya. J Infect Dis. 2012;206: 1020–1029. doi:10.1093/infdis/jis447
- 55. Flasche S, Lipsitch M, Ojal J, Pinsent A. Estimating the contribution of different age
 strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a
 modelling study. BMC Medicine. 2020;18. doi:10.1186/s12916-020-01601-1

- 56. Wyllie AL, Warren JL, Regev-Yochay G, Givon-Lavi N, Dagan R, Weinberger DM. Serotype
 Patterns of Pneumococcal Disease in Adults Are Correlated With Carriage Patterns in
 Older Children. Clinical Infectious Diseases. 2020; doi:10.1093/cid/ciaa1480
- 57. Endo A, Uchida M, Kucharski AJ, Funk S. Fine-scale family structure shapes influenza
 transmission risk in households: Insights from primary schools in Matsumoto city,
 2014/15. PLOS Computational Biology. Public Library of Science; 2019;15: e1007589.
 doi:10.1271/journal.pabi.1007580.
- 616 doi:10.1371/journal.pcbi.1007589
- 58. Weinberger DM, Pitzer VE, Regev-Yochay G, Givon-Lavi N, Dagan R. Association Between
 the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived
 Protection Against Colonization in Toddlers and Preschool-Aged Children. Am J
 Epidemiol. 2019;188: 160–168. doi:10.1093/aje/kwy219
- 621 59. Lees JA, Croucher NJ, Goldblatt D, Nosten F, Parkhill J, Turner C, et al. Genome-wide 622 identification of lineage and locus specific variation associated with pneumococcal
- 623 carriage duration. In: eLife [Internet]. 25 Jul 2017 [cited 24 Jun 2019].
- 624 doi:10.7554/eLife.26255
- 60. Abdullahi O, Wanjiru E, Musyimi R, Glass N, Scott JAG. Validation of Nasopharyngeal
 Sampling and Culture Techniques for Detection of Streptococcus pneumoniae in
 Children in Kenya. Journal of Clinical Microbiology. American Society for Microbiology
 Journals; 2007;45: 3408–3410. doi:10.1128/JCM.01393-07

629

Table 1. Baseline demographic and clinical characteristics of children and adults who were followed up twice weekly for ten months for nasopharynx swabbing for pneumococcal carriage in South African households between 2016 and 2018.

	Total	Younger children	Older children	Adults
Description		<5 years	5-17 years	≥18 years
1	N=1,684	n=279 (16.6%)	n=679 (40.3%)	n=726 (43.1%)
Mean age (SD)	22.1 (±19.8)	2.2 (±1.3)	10.5 (±3.7)	40.5 (±16.7)
Study site				
Agincourt (rural)	849 (50.4)	171 (61.3)	376 (55.4)	302 (41.6)
Klerksdorp (semi-urban)	835 (49.6)	108 (38.7)	303 (44.6)	424 (58.4)
Sex		``````````````````````````````````````	<u> </u>	`, <u>, , , , , , , , , , , , , , , , , , </u>
Female	1,009 (59.9)	137 (49.1)	367 (54.1)	505 (69.6)
Male	675 (40.1)	142 (50.9)	312 (45.9)	221 (30.4)
HIV status				
Negative (-)	1,379 (84.7)	256 (98.5)	634 (95.3)	489 (69.6)
Positive (+)	249 (15.3)	4 (1.5)	31 (4.7)	214 (30.4)
Viral-load based ART status [†]				
Not on ART	93 (40.8)	1 (50.0)	13 (52.0)	79 (39.3)
On ART	135 (59.2)	1 (50.0)	12 (48.0)	122 (60.7)
Self-reported ART status				
Not on ART	30 (13.2)	0 (0.0)	1 (3.8)	29 (14.5)
On ART	198 (86.8)	2 (100.0)	25 (96.2)	171 (85.5)
Mean CD4 count (SD)	673 (±430)	1,210 (±13.4)	857 (±418)	645 (±426)
CD4+ cell count [‡]				
Low	49 (22.8)	0(0.0)	10 (43.5)	39 (20.5)
High	166 (77.2)	2 (100.0)	13 (56.5)	151 (79.5)
Living with ≥ 1 HIV+ adults				
No	818 (48.7)	133 (47.8)	346 (51.1)	339 (46.9)
Yes	860 (51.3)	145 (52.2)	331 (48.9)	384 (53.1)
PCV13 doses received [#]				
At 6 weeks	227 (98.3)	227 (98.3)	N/A	N/A
At 14 weeks	225 (97.4)	225 (97.4)	N/A	N/A
At 9 months	216 (93.5)	216 (93.5)	N/A	N/A
Smoking (≥ 18 years)				
No	505 (69.6)	N/A	N/A	505 (69.6)
Yes	221 (30.4)	N/A	N/A	221 (30.4)
Alcohol use (≥18 years)				
No	417 (57.4)	N/A	N/A	417 (57.4)
Yes	309 (42.6)	N/A	N/A	309 (42.6)


[†] ART use status based on viral load results (on ART = Undetected; Not on ART = <20 copies per ml) [‡] Low CD4+ count \leq 350 cells/mm³ and high CD4+ count >350 cells/mm³ in adults, and low CD4+ count \leq 750 cells/mm³ and high CD4+ count >750 cells/mm³ in children, in HIV-INFECTED only

Pneumococcal conjugate vaccine (PCV13) vaccination status in younger children from available records Standard deviation (SD)

N/A not applicable


Table 2. Effects of included covariates on pneumococcal acquisition and clearance rates estimated in the hidden Markov model.

Description	Hazard Ratio (95%CI) [‡]
Pneumococcal carriage acquisition	
Age in years (y)	
Adult, ≥18y	Referen
Older child, 5-17y	1.15 (1.08-1.2
Younger child, <5y	1.52 (1.38-1.
HIV status	
Negative	Referen
Positive	0.95 (0.87- 1.0
Children living with ≥1 HIV-infected adults	
No	Referen
Yes	0.95 (0.91- 1.0
Place of carriage exposure	
Community	Referen
Within household	1.80 (1.68- 1.9
Household size	
<6 members	Referen
6-10 members	1.05 (1.00-1.
11+ members	1.41 (1.24-1.0
Pneumococcal carriage clearance	
Age in years (y)	
Adult, ≥18y	Referen
Older child, 5-17	0.34 (0.31-0.3
Younger child, <5y	0.10 (0.09-0.
HIV status	
Negative	Referen
Positive	0.52 (0.46-0.1
Antibiotic use	
No	Referen
Yes	1.47 (0.67-3.2
Viral load-based ART status [†]	
Not on ART	Referen
On ART	1.29 (1.13-1.4






634 Figure 1. Susceptible-infected-susceptible (SIS) hidden Markov model schemas of pneumococcal 635 carriage dynamics in South African households between 2016-2018. Continuous-time time-636 homogeneous hidden Markov model where X(t) represents hidden states, and Y(t) observed states, 637 and in which Y(t) is conditionally independent given X(t) and the Markov property holds (A). 638 Pneumococcal nasopharynx (NP) carriage sequence of a specified individual representing hidden and 639 observed states, with a probability that an individual truly carrying a pneumococcal serotype may be 640 detected negative by a real-time quantitative polymerase chain reaction test (B). An SIS hidden 641 Markov model structure that captures a snapshot of part A and carriage sequence of part B in order to 642 estimate transition rates and probability of misclassification/false negative (C). Transition intensity 643 matrix, Q, and emission matrix, E, respectively capture the SIS model transition rates and emission or 644 misclassification probability in part C to compute the maximum likelihood estimates of transition 645 intensities and misclassification probability (D). 646



648 Figure 2. Human immunodeficiency virus (HIV)-stratified pneumococcal carriage dynamics in 649 younger children (<5 years-old), older children (5-17 years-old) and adults (≥18 years-old) in South 650 African households between 2016-2018. Age and HIV-stratified pneumococcal carriage prevalence 651 by different nasopharyngeal sampling visits (A), the likelihood of detecting pneumococcal carriage 652 during visits (B), pneumococcal carriage prevalence by household sizes with 95% confidence 653 intervals (CI) (C) and carriage densities with mean (black diamond), median and associated 95%CI of median, 25th and 75th percentiles, minimum and maximum, and outlier where carriage density is 654 655 measured as genome equivalents per millilitre (GE/ml) (D). Age and antiretroviral therapy (ART) 656 stratified carriage density with mean (red diamonds), median and associated 95%CI of median, 25th and 75th percentiles, minimum and maximum, and outlier (notched boxplot) (E) 657 658



660 Figure 3. Community and within household (HH) acquisitions of pneumococcal carriage in younger


children (<5 years-old), older children (5-17 years-old) and adults (≥18 years-old) in South African

households between 2016-2018. Age and human immunodeficiency virus (HIV) stratified estimates
of community carriage acquisition probability per day (A) and within household carriage acquisition
probability per day over the total follow-up period (B), comparing household without HIV-infected

adult(s) (HIV-) to households with HIV-infected adult(s) (+).

666

659



667

Figure 4. Duration of pneumococcal carriage in younger children (<5 years-old), older children (5-17
years-old) and adults (≥18 years-old) in South African households between 2016-2018. Age and
human immunodeficiency virus (HIV) stratified average carriage duration in days comparing
individuals on antibiotics (ABX) (triangular shape) to those not on ABX (circular shape) (A), and
individuals on antiretroviral therapy (ART) (triangle shape) to those not on ART (circle shape) (B).
Age and HIV stratified overall average carriage duration in days (C). Age and HIV stratified daily
probability of carriage clearance (D).